Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
4.950
0.00 (0.00%)
At close: May 22, 2026, 4:00 PM EDT
4.590
-0.360 (-7.27%)
Pre-market: May 26, 2026, 4:52 AM EDT
Aptevo Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
33
Market Cap
5.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 3.11M | -9.18M | -74.67% |
| Dec 31, 2021 | 12.29M | 7.98M | 185.26% |
| Dec 31, 2020 | 4.31M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 23.07M | 8.41M | 57.37% |
| Dec 31, 2017 | 14.66M | 4.67M | 46.80% |
| Dec 31, 2016 | 9.99M | -23.62M | -70.28% |
| Dec 31, 2015 | 33.60M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Moolec Science | 7.83M |
| CollPlant Biotechnologies | 2.37M |
| BioAtla | 2.00M |
| Bio Green Med Solution | 1.53M |
| XTL Biopharmaceuticals | 968.00K |
| Silo Pharma | 72.10K |
| Alaunos Therapeutics | 3.00K |
| Virax Biolabs Group | 2.99K |
APVO News
- 12 days ago - Aptevo Therapeutics reports Q1 cash and cash equivalents $14.5M - TheFly
- 12 days ago - Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection - Accesswire
- 19 days ago - Aptevo reports 87% clinical benefit in frontline AML patients in RAINIER trial - TheFly
- 19 days ago - Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection - Accesswire
- 2 months ago - Aptevo Therapeutics reports FY25 EPS ($87.27) vs. ($31,460.23) last year - TheFly
- 2 months ago - Aptevo Therapeutics sees cash runway into 4Q26 - TheFly
- 2 months ago - Aptevo Provides State of the Business Report and 2025 Financial Results - Accesswire
- 2 months ago - Aptevo to Participate in March 2026 Conferences - Accesswire